enGene Therapeutics Inc.

ENGN

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001980845

SEC filings (opens in a new tab)

In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.

Other share classesENGNW

Superinvestors holding ENGN, Q2 2026

See all superinvestors

No superinvestor reported holding ENGN in Q2 2026.